Zydus Cadila has received final approval from the US health regulator to market Carbidopa tablets, used for treating symptoms of Parkinson's disease.
Parkinson's symptoms include shakiness, stiffness and difficulty in moving.
Zydus Cadila has received the final approval from the USFDA to market Carbidopa tablets (25 mg), the company said in a BSE filing.
The approved product will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.
The Zydus group has more than 190 approvals and so far filed over 320 abbreviated new drug applications (ANDAs) since it started filings in 2003-04.
Shares of Cadila Healthcare, the listed entity of the group, were up 0.31 per cent at Rs 401.75 per scrip on BSE today.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)